1887

Abstract

One of the main limitations of the vaccination of neonates from vaccinated or infected mothers is the interference by inherited maternal antibodies, which are known to inhibit the immune response against both live and inactivated vaccines. The efficiency of bypassing this inhibition by the transfer of an immunogenic glycoprotein gene, the gD gene of pseudorabies virus (PRV), into neonates was explored. The experiments were conducted in 1- day-old piglets, which are immunocompetent at birth. The same transcription unit (gD of PRV under the control of the adenovirus major late promoter) was delivered intramuscularly at birth either in the form of naked DNA or cloned in the genome of a replication-defective adenovirus. A booster injection of a conventional live PRV vaccine strain was given at 10 weeks of age, the replication of which was greatly restricted by the residual amounts of colostral antibodies in control animals. Piglets were challenged at the age of 16 weeks with a virulent PRV strain. The replication-defective adenovirus was able to efficiently prime piglets born to immune dams against gD in such a way that inoculation with the Bartha strain protected them against a subsequent challenge with the same level of efficacy in piglets born to naive or immune dams. In contrast, piglets born to immune dams into which the gD gene was not transferred, or transferred as naked DNA at birth, were not protected. These results open the way for early immunization of neonates born to vaccinated or infected mothers.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-12-3303
1997-12-01
2022-08-10
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/12/9400981.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-12-3303&mimeType=html&fmt=ahah

References

  1. Adam M., Le Potier M. F., Eloit M. 1994; Vaccination of pigs with replication-defective adenovirus vectored vaccines : the example of pseudorabies. Veterinary Microbiology 42:205–215
    [Google Scholar]
  2. Ali M., Lemoine N. R., Ring C. J. A. 1994; The use of DNA viruses as vectors for gene therapy. Gene Therapy 1:367–384
    [Google Scholar]
  3. Ambriovic A., Adam M., Monteil M., Paulin D., Eloit M. 1997; Efficacy of replication defective vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells. Virology in press
    [Google Scholar]
  4. Andries K., Pensaert M. B., Vandeputte J. 1978; Effect of experimental infection with pseudorabies (Aujeszky’s disease) virus on pigs with maternal immunity from vaccinated sows. American Journal of Veterinary Research 39:1282–1285
    [Google Scholar]
  5. Coe N. E., Mengeling W. L. 1990; Mapping and characterization of neutralizing epitopes of glycoproteins gIII and gp50 of the Indiana-Funkhauser strain of pseudorabies virus. Archives of Virology 110:137–142
    [Google Scholar]
  6. Danko I., Wolff J. A. 1994; Direct gene transfer into muscle. Vaccine 12:1499–1502
    [Google Scholar]
  7. Davis H. L., Whalen R. G. 1995; DNA-based immunization. In Molecular and Cell Biology of Human Gene Therapeutics pp. 368–387 Dickson G. Edited by London: Chapman & Hall;
    [Google Scholar]
  8. Eloit M., Fargeaud D., L’Haridon R., Toma B. 1988; Identification of pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies. Archives of Virology 99:45–56
    [Google Scholar]
  9. Eloit M., Fargeaud D., Vannier P., Toma B. 1989; Development of an ELISA test to differentiate between animals either vaccinated with or infected by Aujeszky’s disease virus. Veterinary Record 28:91–94
    [Google Scholar]
  10. Eloit M., Gilardi-Hebenstreit P., Toma B., Perricaudet M. 1990; Construction of a defective adenovirus vector expressing the pseudorabies virus gp50 and its use as a live vaccine. Journal of General Virology 71:2179–2183
    [Google Scholar]
  11. Ganne V., Eloit M., Laval A., Adam M., Trouve G. 1994; Enhancement of the efficacy of a replication defective adenovirus vectoredvaccine by the addition ofoil adjuvants. Vaccine 12:1190–1196
    [Google Scholar]
  12. Ghiasi H., Cai S., Slanima S., Nesburn A. B., Wechsler S. L. 1996; Vaccination of mice with herpes simplex type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Research 28:147–157
    [Google Scholar]
  13. Gilgenkrantz H., Duboc D., Juillard V., Couton D., Pavirani A., Guillet J. G., Briand P., Kahn A. 1995; Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors - role of the immune response. Human Gene Therapy 6:1265–1274
    [Google Scholar]
  14. Graham F. L., Smiley J., Russel W. C., Nairn R. 1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 36:59–72
    [Google Scholar]
  15. Haddada E., Lopez M., Martinache C., Ragot T., Abina M. A., Perricaudet M. 1993; Efficient adenovirus-mediated gene transfer into human blood monocyte-derived macrophages. Biochemical and Biophysical Research Communications 3:1174–1183
    [Google Scholar]
  16. Ishii H., Kobayashi Y., Kuroki M., Kodama Y. 1988; Protection of mice from lethal infection with Aujeszky’s disease virus by immunization with purified gVI. Journal of General Virology 69:1411–1414
    [Google Scholar]
  17. Juillard V., Villefroy P., Godfrin D., Pavirani A., Venet A., Guillet J. G. 1995; Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. European Journal of Immunology 25:3467–3473
    [Google Scholar]
  18. Kasseisler A., Falckpedersen E., Elfenbein D. H., Alvira M., Buttrick P. M., Leinwand L. A. 1994; The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Therapy 1:395–402
    [Google Scholar]
  19. Lowrie D. B., Tascon R. E., Colston M. J., Silva C. L. 1994; Towards a DNA vaccine against tuberculosis. Vaccine 12:1537–1540
    [Google Scholar]
  20. Marchioli C., Yancey R., Petrovskis E., Timmins J., Post L. 1987; Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky’s disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells. Journal of Virology 61:3977–3982
    [Google Scholar]
  21. Monteil M., Le Potier M. F., Guillotin J., Cariolet R., Houdayer C., Eloit M. 1996; Genetic immunization of seronegative one-day-old piglets against pseudorabies induces neutralizing antibodies but not protection and is ineffective in piglets from immune dams. Veterinary Research 27:443–452
    [Google Scholar]
  22. Riviere M., Tartaglia J., Perkus M., Norton E., Bongermino C., Lacoste F., Duret C., Desmettre P., Paoletti E. 1992; Protection of mice and swine from pseudorabies virus by vaccinia virus-based recombinants. Journal of Virology 66:3424–3434
    [Google Scholar]
  23. Stellmann C., Vannier P., Chappuis G., Brun A., Dauvergne M., Fargeaud D., Bugand M., Colson X. 1989; The potency testing of pseudorabies vaccines in pigs. A proposal for a quantitative criterion and a minimum requirement. Journal of Biological Standards 17:17–27
    [Google Scholar]
  24. Ulmer J. B., Donelly J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., Dewitt C. M., Friedman A., Hawe L. A., Leander K. R., Martinez D., Perry H. C., Shiver J. W., Montgomery D. L., Liu M. A. 1993; Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749
    [Google Scholar]
  25. Ulmer J. B., Deck R. R., Dewitt C. M., Friedman A., Donnelly J. J., Liu M. A. 1994; Protection immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 12:1541–1544
    [Google Scholar]
  26. Vannier P., Hutet E., Bourgueil E., Cariolet R. 1991; Level of virulent virus excreted by infected pigs previously vaccinated with different glycoprotein deleted Aujeszky’s disease vaccines. Veterinary Microbiology 29:213–223
    [Google Scholar]
  27. Vannier P., Hutet E., Cariolet R. 1995; Influence of passive immunity on pig immunization with deleted Aujeszky’s disease vaccines measured by the amount of wild virus excretion after challenge. Veterinary Microbiology 43:53–63
    [Google Scholar]
  28. Wathen M. W., Wathen L. M. K. 1984; Isolation, characterisation and physical mapping of a pseudorabies virus mutant containing antigenically altered gp50. Journal of Virology 51:57–62
    [Google Scholar]
  29. Yang Y. P., Nunes F. A., Berencsi K., Gonczol E., Engelhardt J. F., Wilson J. M. 1994; Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genetics 7:362–369
    [Google Scholar]
  30. Yang Y., Li Q., Ertl H. C., Wilson J. M. 1995; Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. Journal of Virology 69:2004–2015
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-12-3303
Loading
/content/journal/jgv/10.1099/0022-1317-78-12-3303
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error